Pharnext Logo

Pharnext

ALPHA | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0011191287 (+4 more)
LEI:
969500KJGF9ZUYXSMJ27
Country:
France
Address:
9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Our company Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs. Our drug Candidates Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimer’s disease. Both of our lead assets originated from the Pleotherapy R&D approach.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-27 13:00
Legal Proceedings Report
Ouverture d'une procédure de liquidation judiciaire
French 194.1 KB
2024-08-01 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 189.9 KB
2024-07-18 18:00
Capital/Financing Update
Point concernant l'accord de financement en obligations convertibles accordé pa…
French 194.2 KB
2024-07-15 18:00
Legal Proceedings Report
Demande d'ouverture d'une procédure de liquidation judiciaire
French 193.2 KB
2024-07-10 08:00
Capital/Financing Update
Pharnext fait un point sur sa situation financière
French 191.6 KB
2024-07-04 20:00
Legal Proceedings Report
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
French 232.3 KB
2024-07-03 08:00
Capital/Financing Update
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
French 208.2 KB
2024-07-01 18:30
Share Issue/Capital Change
Information relative au nombre total de droits de vote et d'actions composant l…
French 185.7 KB
2024-06-28 08:00
Legal Proceedings Report
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
French 209.3 KB
2024-06-18 18:30
Post-Annual General Meeting Information
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
French 194.9 KB
2024-06-05 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 181.3 KB
2024-05-29 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.9 KB
2024-05-07 19:10
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.6 KB
2024-05-06 18:00
Pre-Annual General Meeting Information
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
French 194.7 KB
2024-05-02 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 195.4 KB

Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharnext via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Israel TMIS
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.